Evolocumab reduces LDL in patients with type 2 diabetes and hyperlipidemia

Treatment with evolocumab significantly reduced low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipid levels, but had no significant impact on blood glucose readings at home. Chinese patients with type 2 diabetes and hyperlipidemia or mixed dyslipidemia. Diabetes, obesity and metabolism.

Previous studies have shown that evolocumab, a human monoclonal antibody, significantly reduces LDL-C without affecting objective measures of glycemic control in patients with and without diabetes. The present study evaluated the efficacy and safety of evolocumab badociated with atorvastatin background in 453 patients randomized to receive atorvastatin of origin (20 mg). / day) more than subcutaneous evocumab at 140 mg every 2 weeks, evolocumab at 420 mg every month and placebo every 2 weeks. or a placebo every month. The final endpoints were the percentage change in LDL-C from baseline to week 12 and baseline to the mean of weeks 10 and 12.

The results showed that at week 12, evolocumab significantly reduced LDL-C compared with placebo (every 2 weeks, -85.0%, monthly, -74.8%). LDL-C concentrations were reduced to <70 mg / dL (1.8 mmol / L) in 96.4% and 95.1% of patients in the evolocumab group every two weeks and every month, respectively. at week 12 and at 97.2% and 95.3% at average 10 and 12-year weeks. Cholesterol levels of non-high-density lipoprotein, apolipoprotein B100, total cholesterol, lipoproteins (a), triglycerides, high density lipoprotein cholesterol and very low density lipoprotein also showed a significant improvement over evolocumab compared with placebo.

"Although this study was limited to a 12-week follow-up, the efficacy and safety results are consistent with previous pre-specified and pre-specified evaluative studies of evolocumab in patients [type 2 diabetes] who have a larger sample and / or a longer duration, "wrote the researchers.

This study was funded by Amgen Inc, which markets the subcutaneous evolocumab.

Reference

Chen Y, Yuan Z, Lu J et al. Randomized study on evolocumab in patients with type 2 diabetes and dyslipidemia on a background statin: predefined badysis of the Chinese population from the BERSON clinical trial [published online March 9, 2019]. Diabetes Obes Metab. doi: 10.1111 / dom.13700

This article originally appeared in Endocrinology Advisor